Renée Raaijmakers

Ms. Renée Raaijmakers

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RRRenée Raaijmakers
Renée Raaijmakers
LRLise Ripken
Lise Ripken
CAC. Rosanne M. Ausems
C. Rosanne M. Ausems
DWDerick G. Wansink
Derick G. Wansink
CRISPR/Cas technology holds promise for the development of therapies to treat inherited diseases. Myotonic dystrophy type 1 (DM1) is a severe neuromuscular disorder with a variable multisystemic character for which no cure is yet available. Here, we review CRISPR/Cas-mediated approaches that target the unstable (CTG•CAG)n repeat in the DMPK/DM1-AS gene pair, the autosomal dominant mutation that causes DM1. Expansion of the repeat results in a complex constellation of toxicity at the DNA level, an altered transcriptome and a disturbed proteome. To restore cellular homeostasis and ameliorate DM1 disease symptoms, CRISPR/Cas approaches were directed at the causative mutation in the DNA and the RNA. Specifically, the triplet repeat has been excised from the genome by several laboratories via dual CRISPR/Cas9 cleavage, while one group prevented transcription of the (CTG)n repeat through homology-directed insertion of a polyadenylation signal in DMPK. Independently, catalytically deficient Cas9 (dCas9) was recruited to the (CTG)n repeat to block progression of RNA polymerase II and a dCas9-RNase fusion was shown to degrade expanded (CUG)n RNA. We compare these promising developments in DM1 with those in other microsatellite instability diseases. Finally, we look at hurdles that must be taken to make CRISPR/Cas-mediated editing a therapeutic reality in patients.

22 September 2025 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
LRLisa Rahm
Lisa Rahm
MHMelissa A. Hale
Melissa A. Hale
RRRenée Raaijmakers
Renée Raaijmakers
AQAlexandra Marrero Quiñones
Alexandra Marrero Quiñones
TPTejal Patki
Tejal Patki
KMKarlien Mul
Karlien Mul

1 July 2016 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
VDValerio D'Amore
Valerio D'Amore
RRRenée Raaijmakers
Renée Raaijmakers
ISInes Santolini
Ines Santolini
CRClementina M. van Rijn
Clementina M. van Rijn
RNRichard Teke Ngomba
Richard Teke Ngomba
GLGilles van Luijtelaar
Gilles van Luijtelaar

1 December 2019 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
CACornelia Rosanne Maria Ausems
Cornelia Rosanne Maria Ausems
RRRenée Raaijmakers
Renée Raaijmakers
WBWalterus Johannes Antonius Adriana van Den Broek
Walterus Johannes Antonius Adriana van Den Broek
MWMarieke Willemse
Marieke Willemse
BEBaziel Gerardus Maria van Engelen
Baziel Gerardus Maria van Engelen
Hans Van BokhovenHans Van Bokhoven
Hans Van Bokhoven
Pericytes are multipotent, vessel-associated progenitors that exhibit high proliferative capacity, can cross the blood-muscle barrier, and have the ability to home to muscle tissue and contribute to myogenesis. Consequently, pericyte-based therapies hold great promise for muscular dystrophies. A complex multi-system disorder exhibiting muscular dystrophy for which pericytes might be a valuable cell source is myotonic dystrophy type 1 (DM1). DM1 is caused by an unstable (CTG)n repeat in the DMPK gene and characterized by skeletal muscle weakness, muscle wasting, and myotonia. We have successfully isolated alkaline phosphatase-positive pericytes from skeletal muscle of DM1 patients and a transgenic mouse model. Intranuclear (CUG)n RNA foci, a pathogenic DM1 hallmark, were identified in human and mouse pericytes. Notably, pericytes from DM1 patients maintained similar growth parameters and innate myogenic characteristics in vitro compared to cells from unaffected controls. Our in vitro results thus demonstrate the potential of pericytes to ameliorate muscle features in DM1 in a therapeutic setting.

19 June 2026 in Stem Cell Research
Verified
Journal Article
Open access
LRLisa Rahm
Lisa Rahm
THThomas D. Hoekman
Thomas D. Hoekman
MWMarieke Willemse
Marieke Willemse
SASilvia Albert
Silvia Albert
DWDerick G. Wansink
Derick G. Wansink
RRRenée Raaijmakers
Renée Raaijmakers
An expanded CTG repeat in the Dystrophia Myotonica Protein Kinase (DMPK) gene is associated with myotonic dystrophy type 1 (DM1), an autosomal dominant neuromuscular disorder characterised by progressive muscle weakness, myotonia, cognitive decline, and a variety of other manifestations. Here, we report the generation of isogenic induced pluripotent stem cell (iPSC) lines, derived from patient DM1 iPSC lines carrying varying expanded (CTG)n repeats in DMPK. These gene-edited isogenic iPSC lines, in which the pathogenic repeat has been excised, serve as a reference for assessing DM1-associated phenotypes in relevant differentiated cell types, such as muscle progenitor cells and neurons.